Short Interest Update on Esperion Therapeutics (ESPR)

Esperion Therapeutics (ESPR) has 2,856,956 shares of shorts outstanding as on August 15, 2016, with 10 days left to cover or roll them over. On Jul 29, 2016, the open interest of short positions was 2,917,808 shares. The stock has a decent trading volume of 294,742 shares daily. The marginal decrease in the short positions is by -2.1%, which amounts to -60,852 shares. Short positions are 19.6% of the available float. The short interest information was released on Wednesday Aug 24th after the market close.

Esperion Therapeutics (NASDAQ:ESPR): The stock opened at $11.20 on Wednesday but the bulls could not build on the opening and the stock topped out at $11.87 for the day. The stock traded down to $10.74 during the day, due to lack of any buying support eventually closed down at $10.88 with a loss of -3.63% for the day. The stock had closed at $11.29 on the previous day. The total traded volume was 423,164 shares.


In a related news, Mcgovern Mark E, director of Esperion Therapeutics, Inc. had purchased 5,000 shares on July 5, 2016 in a transaction. The price per share was $10 and the total amount of the disclosed transaction was $50,000.The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing. This information is based on open market transaction at the market prices.

Esperion Therapeutics, Inc. is a pharmaceutical company focused on developing and commercializing oral, low-density lipoprotein cholesterol (LDL-cholesterol) lowering therapies for the treatment of patients with hypercholesterolemia and other cardio-metabolic risk markers. The Companys primary activities include conducting research and development activities, including nonclinical, preclinical and clinical testing, performing business and financial planning, recruiting personnel, and raising capital. ETC-1002, the Companys lead product candidate, is an orally available, once-daily small molecule designed to lower LDL-cholesterol levels and avoid the side effects associated with other LDL-cholesterol lowering therapies currently available. ETC-1002 is being developed for patients with hypercholesterolemia. One completed Phase IIb clinical study and a second that is nearing completion build upon a Phase I and Phase II clinical development program for ETC-1002.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.